Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S. Grasso, Antoni Ribas, Phuong Tran et al.|Cancer Cell|2020Cited by 379
Dissecting the treatment-naive ecosystem of human melanoma brain metastasisJana Biermann, Peter Canoll, Johannes C. Melms et al.|Cell|2022Cited by 216
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy BiomarkersLisa H. Butterfield, Mary L. Disis, A. Karolina Palucka et al.|Clinical Cancer Research|2011Cited by 109
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanomaSapna P. Patel, Craig L. Slingluff|Journal for ImmunoTherapy of Cancer|2021Cited by 61
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and BevacizumabAubrey G. Wagenseller, Craig L. Slingluff, Amber L. Shada et al.|Journal of Translational Medicine|2013Cited by 25